Atossa Therapeutics Secures Patent for (Z)-Endoxifen
![Atossa Therapeutics Secures Patent for (Z)-Endoxifen](https://investorshangout.com/images/blog/ihnews-Atossa%20Therapeutics%20Secures%20Patent%20for%20%28Z%29-Endoxifen.jpg)
Atossa Therapeutics Secures New Patent for (Z)-Endoxifen
Atossa Therapeutics, Inc. (NASDAQ: ATOS) has recently announced significant news regarding its patent portfolio. The United States Patent and Trademark Office (USPTO) awarded a new patent (U.S. Patent No. 12,071,391) that focuses on compositions involving (Z)-endoxifen, specifically comprising both free base and salt forms of the compound. Importantly, this patent also protects methods of administering these compositions to patients, solidifying Atossa's innovative approach in oncology.
Expansion of Patent Protection
Steven Quay, M.D., Ph.D., the President and CEO of Atossa, expressed enthusiasm about this recent patent, noting that this issuance broadens Atossa's patent protection to include (Z)-endoxifen salt compositions alongside methods for their use. This strategic expansion is expected to enhance long-term shareholder value, reinforcing Atossa’s commitment to innovation and drug development in oncology, particularly in the area of breast cancer.
Understanding (Z)-Endoxifen
(Z)-endoxifen is recognized as a powerful Selective Estrogen Receptor Modulator (SERM), known for its effectiveness in targeting estrogen receptors while also provoking estrogen receptor degradation. In clinical settings, it has demonstrated efficacy, especially in patients exhibiting tumor resistance to standard hormonal treatments, making it a vital player in cancer therapeutics.
Mechanism of Action
Not only does (Z)-endoxifen exert strong anti-estrogen effects, but it also interacts with protein kinase C beta 1 (PKC?1), a known oncogenic protein, at concentrations that are clinically relevant. Remarkably, (Z)-endoxifen has been noted for delivering comparable, if not superior, bone agonistic outcomes while minimizing endometrial proliferative effects when contrasted with treatments like tamoxifen.
Development of Oral Formulation
Atossa is at the forefront of developing an oral formulation of (Z)-endoxifen that streamlines the therapeutic process by not requiring liver metabolism to achieve necessary concentration levels. This innovative formulation is designed to bypass the stomach, as acidic conditions can convert a large portion of (Z)-endoxifen into its inactive variant, (E)-endoxifen. Early Phase 1 studies have indicated that Atossa's oral (Z)-endoxifen is well tolerated in patients.
Current Clinical Trials
The ongoing research encompasses four Phase 2 clinical trials: one study examines healthy women with measurable breast density, another focuses on women diagnosed with ductal carcinoma in situ, and the remaining two trials include the EVANGELINE study, which investigates (Z)-endoxifen's effects in women diagnosed with ER+/HER2- breast cancer. Through these various initiatives, Atossa’s (Z)-endoxifen is protected by four issued U.S. patents along with numerous pending applications, solidifying its market position.
Company Overview
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to pioneering new medicines that address significant unmet medical needs within oncology, particularly in combating breast cancer utilizing (Z)-endoxifen technologies. For further information on Atossa’s innovative approaches, more details can be explored at their official website.
Contact Information
For inquiries, interested parties can reach out to Michael Parks, VP of Investor and Public Relations, at 484-356-7105 or via email at michael.parks@atossainc.com.
Frequently Asked Questions
What is the significance of the new patent for Atossa Therapeutics?
The new patent secures additional protection for (Z)-endoxifen compositions, enhancing Atossa’s intellectual property framework and potential market position.
What is (Z)-endoxifen, and how does it work?
(Z)-endoxifen is a potent SERM that inhibits estrogen receptors and induces their degradation, proving effective even in hormone-resistant tumors.
How is Atossa developing (Z)-endoxifen?
Atossa is formulating a proprietary oral version of (Z)-endoxifen that bypasses the liver metabolism and acidic stomach environment, aiming for therapeutic efficacy.
What clinical trials are currently underway for (Z)-endoxifen?
There are four active Phase 2 trials investigating the efficacy of (Z)-endoxifen in diverse patient populations, including those with different breast cancer diagnoses.
Who can be contacted for more information about Atossa Therapeutics?
Michael Parks, VP of Investor and Public Relations, can be contacted for further information regarding Atossa Therapeutics and its developments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Growth Forecast for Cosmetic Packaging Machinery Market
- Battery Market Forecast to Reach USD 680.85 Billion
- Recent Net Asset Value Announcement for Hargreave Hale AIM VCT
- Pixalate Reveals Top Grossing CTV Apps for 2024
- Comun Expands Services with New Funding for Immigrant Support
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- Pinpoint Digital, LLC Transforms Online Presence with New Website
- Security Robots Market Set for Growth to USD 29.65 Billion
- ACF III slhf. Releases Half-Year Report for 2024
- Top Stocks Outperforming Nvidia in the Market